CurrentAmeriHealth CaritasPolicy CCP.1522

Sacral nerve modulation/stimulation

Customize your policy alerts

Sign up for AmeriHealth Caritas Policy CCP.1522 alerts

Get alerted when Policy CCP.1522 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines AmeriHealth Caritas coverage stance and medical necessity criteria for sacral nerve stimulation (sacral neuromodulation) for adults and discusses investigational uses and contraindications; intended for clinicians and utilization reviewers determining coverage.

Policy Summary

PayerAmeriHealth Caritas

PolicySacral nerve modulation/stimulation

Policy CodePolicy CCP.1522

Change TypeNo material change

Effective DateMar 1, 2023

Last ReviewFeb 1, 2026

Next Review DateJun 1, 2027

Key ActionObtain prior authorization and document a ≥50% symptom reduction on a percutaneous stimulation test plus failure of conservative therapies before permanent implantation.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAmeriHealth CaritasPolicy CCP.1522

Sacral nerve modulation/stimulation

Customize your policy alerts

Sign up for AmeriHealth Caritas Policy CCP.1522 alerts

Get alerted when Policy CCP.1522 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmeriHealth Caritas

PolicySacral nerve modulation/stimulation

Policy CodePolicy CCP.1522

Change TypeNo material change

Effective DateMar 1, 2023

Last ReviewFeb 1, 2026

Next Review DateJun 1, 2027

Key ActionObtain prior authorization and document a ≥50% symptom reduction on a percutaneous stimulation test plus failure of conservative therapies before permanent implantation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

>=50%responder threshold

18+age requirement

35.2%revision rate (fecal review)

19.7%explantation rate (fecal review)

~20+references cited

multiplecodes listed

Coverage and Medical Necessity Criteria

Adults — overactive bladder, nonobstructive urinary retention, urgency urinary incontinence

Covered when ALL of the following are met

Adult urinary indications: Member is age 18 years or older

Indications: Diagnosis of severe, refractory overactive bladder syndrome, nonobstructive urinary retention, or urgency urinary incontinence

Guidelines position sacral nerve stimulation as a third-line intervention

Therapeutic trial response: Percutaneous stimulation test demonstrates at least a 50% reduction in incontinence symptoms as documented in voiding diaries>= 50%

Required prior to permanent implantation

Conservative therapy failure: More conservative first- and second-line approaches (behavioral therapies, pharmacotherapy, tibial nerve stimulation, botulinum toxin when appropriate) are ineffective, not tolerated, refused, or contraindicated

Patient willing to undergo a surgical procedure

Adults — fecal incontinence

Covered when ALL of the following are met

Adult fecal indication: Member is age 18 years or older with fecal incontinence

Per professional guidelines support; considered a treatment option

Therapeutic trial response (fecal): Percutaneous stimulation test demonstrates at least a 50% reduction in fecal incontinence episodes as documented in bowel diaries>= 50%

Required prior to permanent implantation

Conservative therapy failure (fecal): More conservative first- and second-line approaches (lifestyle/dietary measures, pelvic floor therapy, stool bulking agents/antidiarrheals, tibial nerve stimulation, transanal irrigation, anal inserts) are ineffective, not tolerated, refused, or contraindicated

Patient willing to undergo a surgical procedure

Not medically necessary — Stress urinary incontinence

Not covered for the following indication

Stress urinary incontinence: Sacral nerve stimulation for stress urinary incontinence is investigational/not clinically proven and therefore not medically necessary

Not approved by the U.S. Food and Drug Administration for stress urinary incontinence

All other uses of sacral nerve stimulation that are not specifically listed as medically necessary in this policy are considered investigational/not clinically proven and therefore not medically necessary.

The document provides clinical references and cites FDA device approvals and guidance sources but does not enumerate additional explicit exclusions within this references section; cited materials include NICE guidance, device approvals, and systematic reviews that support the clinical discussion.

Use of sacral nerve stimulation for stress urinary incontinence and for other indications not identified as covered (including most pediatric indications) is considered investigational and not medically necessary.

Within the referenced material and bibliography there are no additional explicit statements labeled as 'not medically necessary' beyond those present in the main policy limitations and coverage sections.

Procedure, Device, and Billing Codes

Commonly submitted CPT codesCPT

64561	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement), including image guidance, if performed.
64581	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement), including image guidance, if performed.
64585	Revision or removal of peripheral neurostimulator electrode array.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.
95970	Electronic analysis of implanted neurostimulator pulse generator; brain, cranial nerve, spinal cord, peripheral nerve, or sacral nerve, without programming.
95971	Electronic analysis with simple programming (1-3 parameters); spinal cord or peripheral nerve (e.g., sacral nerve).

Additional CPT / Category III codesCPT

95972	Electronic analysis with complex programming (4+ parameters); spinal cord or peripheral nerve (e.g., sacral nerve).
0786T	Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance.
0787T	Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator.
0788T	Electronic analysis with simple programming of implanted integrated neurostimulation system; sacral nerve, 1-3 parameters.

HCPCS Level II (C-codes) for devices/suppliesHCPCS

C1767	Generator, neurostimulator (implantable), non-rechargeable.
C1778	Lead, neurostimulator (implantable).
C1787	Patient programmer, neurostimulator.
C1820	Generator, neurostimulator (implantable), with rechargeable battery and charging system.
C1883	Adaptor/extension, pacing lead or neurostimulator lead (implantable).
C1897	Lead, neurostimulator test kit (implantable).

HCPCS Level II - Prosthetic/Device L-codesHCPCS

L8679	Implantable neurostimulator pulse generator, any type.
L8681	Patient programmer (external), replacement only.
L8682	Implantable neurostimulator radiofrequency receiver.
L8684	Radiofrequency transmitter (external) for sacral root neurostimulator, replacement.
L8689	External recharging system for battery (internal), replacement only.

inv-12: Responder threshold during percutaneous stimulation test

Responder threshold>= 50% reduction in incontinence episodes as documented in voiding or bowel diaries

Documentation methodReduction must be documented in patient-recorded voiding diaries (urinary) or bowel diaries (fecal)

Context of useRequired during the percutaneous stimulation (test) phase to determine candidacy for permanent implantation

Applies toAdults (age 18 and older) being evaluated for sacral nerve stimulation for urinary or fecal incontinence

Prior Authorization, Documentation, and Billing Requirements

Prior Authorization

Prior authorization required for permanent implantation

Prior authorization is required to confirm medical necessity before permanent implantation when review is needed to verify a qualifying percutaneous stimulation test response (≥50% reduction in incontinence symptoms documented in voiding or bowel diaries) and failure/intolerance of conservative therapies.

Prior auth applies to permanent implant when therapeutic trial response and conservative therapy failure must be validated.
Documentation of the percutaneous stimulation test result and prior conservative treatments should be included with the authorization request.

Prior Authorization

Prior authorization required for listed procedure and device codes

Prior authorization is required for sacral neuromodulation services and devices billed with the listed CPT and HCPCS codes; providers must obtain authorization per payer policy prior to services.

Commonly submitted CPT codes include: 64561, 64581, 64585, 64590, 64595, 95970, 95971.

Clinical Background and Scope

Pelvic floor dysfunction encompasses a range of anatomic and functional disorders that can cause symptoms such as constipation, urinary and fecal incontinence, and pelvic pain; management typically involves a multidisciplinary, stepwise approach beginning with conservative therapies and reserving sacral neuromodulation as a minimally invasive, third-line option for appropriately selected adults with refractory symptoms.

Definitions and Device Description

inv-23: Sacral nerve stimulation / sacral neuromodulation — definition and brief description

DefinitionPlacement of electrical stimulation targeting an S3 foramen via an implantable device (sacral neuromodulation/sacral nerve stimulation)

PurposeTo restore or modulate sacral nerve signaling to the brain for treatment of pelvic floor disorders such as overactive bladder, urinary retention, urgency urinary incontinence, and fecal incontinence

DevicesIncludes FDA‑approved systems such as InterStim, Axonics, VIRTIS, and Neuspera

Procedure characteristicMinimally invasive approach generally preceded by a test stimulation phase before permanent implantation

inv-24: Sacral neuromodulation/sacral nerve stimulation — implantation or percutaneous placement

Procedure description

Policy Revision History

2026-02-01policy reviewLatest

Policy last reviewed; document metadata records a last_review date of 2026-02-01.

2023-03-01effective_date

Policy effective date recorded as 2023-03-01.

2019-11-13device_approval

Policy Summary

PayerAmeriHealth Caritas

PolicySacral nerve modulation/stimulation

Policy CodePolicy CCP.1522

Change TypeNo material change

Effective DateMar 1, 2023

Last ReviewFeb 1, 2026

Next Review DateJun 1, 2027

Key ActionObtain prior authorization and document a ≥50% symptom reduction on a percutaneous stimulation test plus failure of conservative therapies before permanent implantation.

SourceLink

On This Page

Additional CPT/Category III and HCPCS device/supply codes are listed (e.g., 95972, 0786T–0788T; C1767–C1897; L8679–L8689).

Step Therapy

Stepwise therapy—fail first- and second-line conservative treatments first

Policy requires a stepwise (tiered) approach: patients must have failed or not tolerated first- and second-line conservative treatments before trial or implantation of sacral nerve stimulation is considered.

First-line options: behavioral modification, pelvic floor muscle training, bladder training, dietary/lifestyle measures, stool bulking agents for bowel dysfunction.
Second-line nonsurgical interventions: pharmacotherapy, peripheral/tibial nerve stimulation, transanal irrigation, anal inserts, intradetrusor botulinum toxin where appropriate.

Note

Include clinical and coding information with requests

Document and include required clinical information with authorization or claims as applicable; see other callouts for specific documentation expectations.

Include procedure and device codes from the policy when requesting authorization or submitting claims.
Retain and supply supporting documentation that demonstrates medical necessity when requested.

Documentation Required

Document ≥50% symptom reduction during percutaneous stimulation test

Objective documentation of response to the percutaneous stimulation test is required: voiding or bowel diaries must show at least a 50% reduction in incontinence episodes to demonstrate candidacy for permanent implantation.

At least a 50% reduction in symptoms documented in voiding (urinary) or bowel (fecal) diaries during the percutaneous stimulation test is required.

Documentation Required

Document prior conservative therapy attempts and patient discussion

Document prior conservative therapies tried and state that they were ineffective, not tolerated, refused, or contraindicated; also document the patient’s willingness to undergo surgical implantation.

Record which first- and second-line therapies were attempted (behavioral, pharmacologic, tibial nerve stimulation, etc.).
If therapies were not tried, document contraindication, intolerance, or patient refusal and that alternatives were discussed.

Billing Rule

Use listed procedure/device codes and retain supporting documentation

Use the codes listed in the policy as the most commonly submitted and appropriate codes for sacral neuromodulation procedures, devices, and programming; retain documentation supporting medical necessity.

Consult the policy’s CPT and HCPCS code lists when selecting codes (e.g., 64561–64595; 95970–95972; 0786T–0788T; C1767–C1897; L8679–L8689).
Keep clinical records (diaries, prior therapy notes, trial results) to support billing and authorization requests.

Denial Risk

Contraindications that may trigger denial

Absolute contraindications (inadequate clinical response to the therapeutic trial, inability to operate the device or lack of supportive caregivers, pregnancy) and listed relative contraindications may lead to denial of coverage if present and documented.

Absolute contraindications that may trigger denial include: inadequate response to trial, inability to operate device without caregiver support, and pregnancy.
Relative contraindications include progressive neurologic disease, complete spinal cord injury or spina bifida, anticipated need for MRI below the head, or abnormal sacral anatomy.

Billing Rule

Coding and billing compliance to avoid denials or audits

Providers are expected to consult coding manuals and bill using appropriate procedure and device codes; failure to use correct codes or to provide required documentation may trigger claim denials or audits.

Ensure coding aligns with the policy’s listed CPT and HCPCS codes and local coding guidance.
Maintain and submit documentation demonstrating medical necessity to reduce risk of claim denial.

Implantation or percutaneous placement of electrodes and a pulse generator to modulate sacral nerve activity for management of urinary or fecal dysfunction

ComponentsElectrode leads placed at the sacral nerve (typically S3) and a pulse generator (implantable, rechargeable, or externally powered) connected to the leads

IndicationsUsed for refractory overactive bladder, nonobstructive urinary retention, urgency urinary incontinence, and fecal incontinence when criteria are met

Regulatory statusMultiple systems have FDA premarket approvals for various urinary and fecal indications (see device PMAs)

FDA decision date for Axonics Sacral Neuromodulation System premarket approval for urinary indications (P180046).

2019-09-06device_approval

FDA decision date for Axonics premarket approval for fecal incontinence (P190006).

1997-09-29device_approval

FDA premarket approval decision date for InterStim (P970004).

2023-01-11device_approval

FDA decision date for Virtis Sacral Neuromodulation System premarket approval (P170001).

2025-06-17device_approval

FDA decision date for Neuspera Sacral Neuromodulation System premarket approval (P240031) as recorded in references.